Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.

A comparison of efficacies of medroxyprogesterone acetate (MPA) and the antiestrogen tamoxifen (TX) in the therapy for advanced breast cancer in patients who had already previously been intensely treated showed that, as to the objective remissions, the two drugs can be looked upon as equivalent. Nevertheless, with MPA a better analgetic and anabolic effect--a marked improvement in the performance status (Karnofsky index)--was achieved.